5 completed, 3 unknown. 4 Phase 1, 3 Phase 2, 1 Not applicable, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 3, Unknown 1 |
| Phase 2 | 3 | Completed 2, Unknown 1 |
| Not applicable | 1 | Completed 1 |
| Phase 4 | 1 | Unknown 1 |
Follow Poly I-C: new trials by email Literature Review of Poly I-C trials Research Report on Poly I-C
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of PolyIC and PD-1 mAb in Subjects With Unresectable Hepatocellular Carcinoma PD-1 mAb, PolyIC - Carcinoma, Hepatocellular | Phase 2 | Unknown | Second Affiliated Hospital, Zhejiang University, School of Medicine | 60 | 2018-10-22 | 2018-11-16 |
| Combination of Immunization and Radiotherapy for Malignant Gliomas (InSituVac1) Combined immune adjuvants and radiation - High Grade Glioma, Glioblastoma | Phase 1 | Unknown | Beijing Tiantan Hospital | 30 | 2018-04-01 | 2019-07-11 |
| A Safety Study to Compare the Effect of Two PrEP-001 Nasal Powder Formulations on Nasal Mucosa and Serum Cytokine Production PrEP-001 6.4 mg, PrEP-001 3.2 mg, Placebo - Upper Respiratory Tract Infections | Phase 1 | Completed | Prep Biopharm Limited | 20 | 2017-05-08 | 2017-07-02 |
| A Study to Examine the Duration of Effect of PrEP-001 in Healthy Subjects Challenged With HRV-16 PrEP-001, Placebo - Viral Upper Respiratory Tract Infection | Phase 2 | Completed | Prep Biopharm Limited | 102 | 2016-04-06 | 2018-11-09 |
| Antiviral Efficacy of the Combination Treatment With Poly IC and Entecavir for Chronic Hepatitis B Poly IC, Entecavir - Chronic Hepatitis B | Phase 4 | Unknown | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 180 | 2015-07-01 | 2015-08-25 |
| Development of Human Nasal Challenge Models With Microbial Constituents and Grass Pollen Poly ICLC, Poly I:C, R848 - Allergic Rhinitis, Asthma | Not applicable | Completed | Imperial College London | 93 | 2014-03-01 | 2021-11-05 |
| Safety Study of Adjuvant Vaccine to Treat Melanoma Patients NY-ESO-1 protein; Poly-ICLC; Montanide - Melanoma | Phase 1 / Phase 2 | Completed | Nina Bhardwaj | 34 | 2010-09-01 | 2018-02-13 |
| Study of NS-9 in Patients With Liver Metastases NS-9 [Poly I: Poly C] - Liver Neoplasms, Neoplasm Metastasis | Phase 1 | Completed | NS Pharma, Inc. | 20 | 2002-09-01 | 2005-11-11 |
Respiratory Tract Infections (2) · Skin Neoplasms (2) · Asthma (1) · Breast Neoplasms (1) · Carcinogenesis (1) · Carcinoma, Hepatocellular (1) · Colorectal Neoplasms (1) · Esophageal Neoplasms (1) · Glioblastoma (1) · Glioma (1) · Hepatitis B, Chronic (1) · Hypersensitivity (1) · Inflammation (1) · Kidney Neoplasms (1) · Latent Tuberculosis (1)
Prep Biopharm Limited (2) · Beijing Tiantan Hospital (1) · Imperial College London (1) · NS Pharma, Inc. (1) · Nina Bhardwaj (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1)
China (3) · United Kingdom (3) · United States (2)
Anna Pavlick, D.O. (1) · Cyrus Ghobadi, MD (1) · Liang D Yang, M.D. (1) · Litza McKenzie, MBChB BSc (1) · Nina Bhardwaj, MD, PhD (1) · Peijuan Ren, M.D. (1) · Peter JM Openshaw, FRCP, PhD, FRSB, FMedSci (1) · Robin Shattock, PhD (1) · Song Lin, M.D. (1) · Tingbo Liang, MD PhD (1) · Trevor Hansel, FRCPath, PhD (1) · You-Wen He, M.D. Ph.D. (1)